High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

por de Jonge, M E, Huitema, A D R, Beijnen, J H, Rodenhuis, S
Publicado 2006

Assessment of Performance of Manufacturing Procedures in a Unit for Production of Investigational Anticancer Agents, Using a Mixed Effects Analysis

por van der Schoot, S. C., Nuijen, B., Huitema, A. D. R., Beijnen, J. H.
Publicado 2007

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

por Asperen, J van, Tellingen, O van, Tijssen, F, Schinkel, A H, Beijnen, J H
Publicado 1999

CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.

por Beijnen, J. H., Flora, K. P., Halbert, G. W., Henrar, R. E., Slack, J. A.
Publicado 1995

Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.

por van Warmerdam, L. J., Rodenhuis, S., van der Wall, E., Maes, R. A., Beijnen, J. H.
Publicado 1996

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)

por Kuin, A, Rutgers, M, Valk, M A van der, Beijnen, J H, Smets, L A
Publicado 1999

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo

por van Tellingen, O, Buckle, T, Jonker, J W, van der Valk, M A, Beijnen, J H
Publicado 2003

Importance of highly selective LC–MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

por Jager, N. G. L., Rosing, H., Linn, S. C., Schellens, J. H. M., Beijnen, J. H.
Publicado 2012

Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export

por Evers, R, Haas, M de, Sparidans, R, Beijnen, J, Wielinga, P R, Lankelma, J, Borst, P
Publicado 2000

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

por Klaase, J. M., Kroon, B. B., Beijnen, J. H., van Slooten, G. W., van Dongen, J. A.
Publicado 1994

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.

por de Wit, R., Beijnen, J. H., van Tellingen, O., Schellens, J. H., de Boer-Dennert, M., Verweij, J.
Publicado 1996

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

por Terwogt, J M M, Mandjes, I A M, Sindermann, H, Beijnen, J H, ten Bokkel Huinink, W W
Publicado 1999

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG)

por Kuin, A, Aalders, M, Lamfers, M, Zuidam, D J van, Essers, M, Beijnen, J H, Smets, L A
Publicado 1999

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

por Harmsen, Stefan, Meijerman, I., Febus, C. L., Maas-Bakker, R. F., Beijnen, J. H., Schellens, J. H. M.
Publicado 2009

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

por Oostendorp, Roos L., Buckle, T., Lambert, G., Garrigue, J. S., Beijnen, J. H., Schellens, J. H. M., van Tellingen, O.
Publicado 2010

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

por van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., Beijnen, J. H.
Publicado 1997

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

por Tellingen, O van, Huizing, M T, Panday, V R Nannan, Schellens, J H M, Nooijen, W J, Beijnen, J H
Publicado 1999

Evaluation of α(2)-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

por Keizer, Ron J., Funahashi, Y., Semba, T., Wanders, J., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R.
Publicado 2011

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

por Meulendijks, D, Dewit, L, Tomasoa, N B, van Tinteren, H, Beijnen, J H, Schellens, J H M, Cats, A
Publicado 2014

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization

por Verheijen, R. B., Swart, L. E., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., Steeghs, N.
Publicado 2017